
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics is a promising biotechnology company focused on discovering and developing precision oncology therapies. The company is well positioned in the competitive PRMT5 inhibitor category with a compelling frontline registrational strategy in pancreatic cancer and potential development opportunities in other cancers such as non-small cell lung cancer. Upcoming data disclosures and expected initiations for clinical trials further support the company's positive outlook. The strong safety profile of vopimetostat, the company's leading PRMT5 inhibitor, will also differentiate it from other competitors in the market. However, there are potential risks such as R&D setbacks or regulatory delays that could impact the company's success and growth potential. Overall, the achievements and potential of Tango Therapeutics make it a promising investment opportunity with a bright future ahead.
Bears say
Tango Therapeutics is at a disadvantage in the competitive oncology market, with numerous competitors currently present and the constant threat of new drugs emerging. The company's pipeline products may face competition from other similar agents, especially from China, which could potentially reduce its revenues. The company also requires significant funding for its clinical trials, which may lead to potential ownership dilution for investors and carry risks through debt offerings. Additionally, the company's proposed collaborations with RevMed and ERASCA may not be enough to achieve success in the market, and an acquisition by a larger pharmaceutical company may be necessary for Tango to secure a larger upfront payment and secure an exclusive partnership.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares